Insider Transactions in Q2 2024 at Kal Vista Pharmaceuticals, Inc. (KALV)
Insider Transaction List (Q2 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 07
2024
|
Benjamin L Palleiko CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
7,465
-3.22%
|
$82,115
$11.53 P/Share
|
|
Jun 06
2024
|
Benjamin L Palleiko CHIEF EXECUTIVE OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
15,625
+6.31%
|
-
|
|
May 20
2024
|
Christopher Yea CHIEF DEVELOPMENT OFFICER |
SELL
Open market or private sale
|
Direct |
11,610
-12.66%
|
$127,710
$11.76 P/Share
|
|
May 20
2024
|
Benjamin L Palleiko CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
21,959
-9.21%
|
$241,549
$11.76 P/Share
|
|
May 20
2024
|
Paul K. Audhya CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
13,175
-15.78%
|
$144,925
$11.76 P/Share
|
|
May 20
2024
|
Edward P. Feener CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
8,088
-9.99%
|
$88,968
$11.76 P/Share
|
|
May 17
2024
|
Christopher Yea CHIEF DEVELOPMENT OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
18,789
+17.01%
|
-
|
|
May 17
2024
|
Benjamin L Palleiko CHIEF EXECUTIVE OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
51,031
+17.63%
|
-
|
|
May 17
2024
|
Paul K. Audhya CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
30,614
+26.83%
|
-
|
|
May 17
2024
|
Edward P. Feener CHIEF SCIENTIFIC OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
18,789
+18.84%
|
-
|